Screening

A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.

ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.

Your daily dose of the clinical news you may have missed.

Only about 75% of people with a positive result on a stool-based test for colorectal cancer complete screening with a colonoscopy. Fendrick "won't rest" until it's 90%.

Mark Fendrick, MD, thinks that right now, the relative accuracy of blood-based tests for CRC compared with available alternatives is not quite comparable. He explains.

With a population goal of having 80% to 90% of age-eligible Americans screened for colorectal cancer, colonoscopy can not be the initial test for everyone, Fendrick emphasizes.

Your daily dose of the clinical news you may have missed.

Never considered the carbon footprint left by a screening for colorectal cancer? Fendrick has and did the research to learn more. He explains in this short video.

GLP-1 receptor agonists showed promise in lowering obesity-related cancer risks in adults with type 2 diabetes, particularly colorectal cancer.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Results showed that a nanoencapsulated CBD cream reduced UV-A–induced nuclear and mitochondrial DNA damage linked to photoaging in human skin.

Your daily dose of the clinical news you may have missed.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

The increase in stool-based CRC testing is a logical trend, Hendrick said in an interview, given the convenience plus the 2 million younger adults now eligible for screening.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

DDW 2025. Follow-up colonoscopy after a positive stool-based test was superior among adults aged 45-49 and across diverse populations whose original test was mt-sDNA.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

The AI program also correctly identified 90% of true positive cases, according to new data presented at the Society for Breast Imaging's annual symposium.

While smoking in the US continues to decline, the American Cancer Society reports mixed progress in major cancer risk factors, prevention, and screening.

GRAIL announced plans to present new support for the Galleri test's ability to simultaneously screen for multiple cancers plus its accuracy for cancer signal of origin prediction.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences

ACP 2025: Dr Kalager shares strategies for addressing patient beliefs, presenting risk data, and promoting shared decision-making in primary care settings.

The increase in pancreatic cancer among Americans aged 15 to 34 is particularly alarming and should alert clinicians to heed relevant GI symptoms as suspicious.

The phone-based patient navigation intervention addressed barriers to CRC testing follow-up and included patient education.